PM
KRTX

Prosight Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Prosight Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,826
Closed -$1.22M – 55
2020
Q3 		$1.22M Buy
+15,826
New +$1.35M 0.58% 39

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Prosight Management's KRTX Position: Q4 2020 in Review

Prosight Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2020, closing a stake of 15,826 shares — an estimated $1.22M sold.

Prosight Management first reported a position in KRTX in Q3 2020 and held it in 1 quarter. The position peaked at $1.22M in Q3 2020. 143 funds tracked by Wall St. Rank hold KRTX as of Q4 2020.

  • Prosight Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Prosight Management sold 15,826 Karuna Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $1.22M.
  • Prosight Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Prosight Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.22M in Q3 2020.
  • 143 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.